Evolutionary Measures Show that Recurrence of DCIS is Distinct from Progression to Breast Cancer.

Progression from pre-cancers like ductal carcinoma (DCIS) to invasive disease (cancer) is driven by somatic evolution and is altered by clinical interventions. We hypothesized that genetic and/or phenotypic intra-tumor heterogeneity would predict clinical outcomes for DCIS since it serves as the substrate for natural selection among cells. We profiled two samples from two geographically distinct foci from each DCIS in both cross-sectional (N = 119) and longitudinal cohorts (N = 224), with whole exome sequencing, low-pass whole genome sequencing, and a panel of immunohistochemical markers. In the longitudinal cohorts, the only statistically significant predictors of time to non-invasive DCIS recurrence were the combination of treatment (lumpectomy only vs mastectomy or lumpectomy with radiation, HR = 12.13, = 0.003, Wald test with FDR correction), ER status (HR = 0.16 for ER+ compared to ER-, = 0.0045), and divergence in SNVs between the two samples (HR = 1.33 per 10% divergence, = 0.018). SNV divergence also distinguished between pure DCIS and DCIS synchronous with invasive disease in the cross-sectional cohort. In contrast, the only statistically significant predictors of time to progression to invasive disease were the combination of the width of the surgical margin (HR = 0.67 per mm, = 0.043) and the number of mutations that were detectable at high allele frequencies (HR = 1.30 per 10 SNVs, = 0.02). These results imply that recurrence with DCIS is a clinical and biological process different from invasive progression.